Moderna Appoints Tracey Franklin as Chief Human Resources Officer
September 04 2019 - 8:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that Tracey Franklin has been appointed
Chief Human Resources Officer. She will serve on Moderna’s
Executive Committee, reporting to Chief Executive Officer Stéphane
Bancel.
“We are excited to welcome Tracey to Moderna as we continue
making progress across our pipeline and prepare to advance
additional investigational mRNA medicines into Phase 2 clinical
trials,” said Stéphane Bancel, CEO. “Her track record at Merck of
delivering human resources strategies to enable high-performing
research, development, manufacturing and commercial teams globally
will be instrumental as we continue to grow as a biotech company,
advance our pipeline and build late-stage development and
commercial capabilities that will be essential to our future
growth. Tracey has the experience of operating at scale and across
geographies in a science-driven pharmaceutical company and will be
a great partner to ensure we maintain the uniqueness of our
culture.”
Ms. Franklin will join Moderna in
October 2019 following 15 years at Merck & Co., Inc. Most
recently, she led Merck’s global talent strategy as Vice President,
HR Chief Talent and Strategy Officer. In this role Tracey was
responsible for leading the vision, development and execution of
the company’s Talent and Workforce Strategy with a focus on
evolving the organizational culture and talent for the future.
Previous leadership roles included responsibility for HR for all
divisions in the European region, head of HR for the U.K. and
Ireland subsidiaries of Merck, and HR Operations leader responsible
for HR program implementation across Merck’s global footprint. In
these various leadership roles, she was based in Switzerland, the
U.K. and the U.S. and served on Merck’s HR Leadership Team.
“I am thrilled to be joining the Moderna team at such an
important time as they move this unique science and technology
forward to change the course of healthcare for patients and
society. I have spent time with the talented leaders at the company
and I am thoroughly impressed by the sophistication, pace and
breadth of the organization,” said Ms. Franklin. “I look forward to
building upon the good work done to date and continuing to advance
the company’s organizational and talent strategies to ensure we are
best positioned as we grow to have the highest impact on patients
across the globe.”
Ms. Franklin holds a bachelor’s in communication arts and
sciences from Pennsylvania State University and a master’s in
industrial and organizational psychology from Fairleigh Dickinson
University.
About Moderna Moderna is advancing messenger RNA (mRNA)
science to create a new class of transformative medicines for
patients. mRNA medicines are designed to direct the body’s cells to
produce intracellular, membrane or secreted proteins that can have
a therapeutic or preventive benefit and have the potential to
address a broad spectrum of diseases. Moderna’s platform builds on
continuous advances in basic and applied mRNA science, delivery
technology and manufacturing, providing the Company the capability
to pursue in parallel a robust pipeline of new development
candidates. Moderna is developing therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases and
cardiovascular diseases, independently and with strategic
collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca, Plc.
and Merck, Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of Defense; the
Biomedical Advanced Research and Development Authority (BARDA), a
division of the Office of the Assistant Secretary for Preparedness
and Response (ASPR) within the U.S. Department of Health and Human
Services (HHS). Moderna has been ranked in the top ten of Science’s
list of top biopharma industry employers for the past four years.
To learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190904005223/en/
Moderna Contacts: Media: Colleen Hussey Senior
Manager, Corporate Communications 203-470-5620
Colleen.Hussey@modernatx.com Investors: Lavina Talukdar Head of
Investor Relations 617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024